Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers

COVID-19 Clinical Trial

Official title:

Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04461379
• Other study ID #: EN20-00011
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 21, 2020
• Est. completion date: January 1, 2021

Study information

• Verified date: November 2020
• Source: Hospital Universitario Dr. Jose E. Gonzalez
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Mexico the total number of confirmed cases of COVID-19 is 232, 000 and 28,510 deaths. Health workers are at high risk of COVID-19 infection. Their absence from work dramatically limits the ability to contain the disease. There is currently no vaccine to prevent the disease. Since the introduction to the vaccination schedule of the Bacillus Calmette-Guerin (BCG) live attenuated vaccine directed towards tuberculosis prevention, a decrease in infant mortality has been reported, not related only to tuberculosis. BCG vaccine has been hypothesized to have a non-specific role towards other unrelated pathogens such as viruses that cause airway disease, with reduced morbidity and mortality. In murine as well as in human models it has been shown to decrease the incidence of acute respiratory influenza infections. Likewise, in countries with a high endemicity for tuberculosis, the BCG vaccine reduces the incidence of respiratory infections by up to 80% . In healthy subjects, the BCG vaccine increases the production of proinflammatory cytokines in monocytes. Likewise, it increases the epigenetic response, causing an increase in the transcription of genes important in the antimicrobial response, as well as an improvement in cellular function. This is the first national clinical trial to evaluate prospectively the effect that the BCG vaccine offers towards the prevention and reduction of severity in cases of COVID-19.

Description:

The study design is a randomized, double-blinded, placebo-controlled clinical trial. Age stratified randomization (<45 years and> 45 years) was performed using permuted blocks with allocation concealment. The sample size is 908 patients. 454 patients in each stratum (227 with placebo and 227 with BCG vaccine). Eligible participants will be healthcare professionals over 18 years of age who are in contact with patients with COVID-19, with negative IgG and IgM antibodies results for SARS-CoV-2 prior to their inclusion and sign the informed consent. After signing the informed consent, the participants will be randomized 1:1 to the intervention group (BCG vaccine) or control (placebo), a medical history will be performed, and a blood plasma sample will be obtained to determine specific antibodies against SARS-CoV-2. The patients will be followed up for 6 months after the application of the vaccine, they will be contacted by phone every two weeks in order to identify the adverse effects of the vaccine (30 days after the application) as well as to identify symptoms of COVID-19, in addition, follow-up visits will be carried out at the third and sixth months, in each of these visits a blood plasma sample will be obtained and IgG and IgM antibodies will be measured. Statistical Analysis Type: By intention to treatment

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 908
• Est. completion date: January 1, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Health workers who are working onsite in patients' areas with COVID-19
• Age > 18 years
• Negative specific IgG and IgM antibodies test result for SARS CoV-2 before the enrollment.
• Provide a signed and dated informed consent form

Exclusion Criteria:

• Age <18 years
• Positive test for specific antibodies IgG and IgM antibodies result for SARS Cov-2
• Primary or secondary immunosuppression
• Use of immunosuppression drugs, use of hydroxychloroquine, cloroquine, Azithromycin, Lopinavir/ritonavir, Ivermectin or any other drug used to treat patients COVID-19 before the enrollment.
• Chemotherapy treatment
• Presence of antibodies IgA, IgM, IgG against SARS-CoV-2
• Pregnancy or breastfeeding
• Missing informed consent form
• Fever > 38° in the previous 24 hours
• Any BCG vaccine contraindication
• History of previous allergy to the components of the vaccine
• Already part of any other trial
• Previous or active tuberculosis (TB) disease
• Another vaccine administrated 4 months before the start of the trial.
• Any underlying history of malignancy or lymphoma.
• Actual treatment with steroids
• Absence of more than 1 month from the hospital, from the study period.

Related Conditions & MeSH terms

• BCG
• Corona Virus Infection
• Coronavirus Infections
• COVID-19
• SARS-CoV2
• Severe Acute Respiratory Syndrome

Intervention

Biological:
• BCG vaccine
A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)

Other:
• Placebo
A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution

Locations

Country	Name	City	State
Mexico	Hospital Universitario "José E. González"	Monterrey	Nuevo León

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Universitario Dr. Jose E. Gonzalez

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demonstrate COVID- 19 disease incidence among Health care workers:	Cumulative incidence of infection in 6 months: disease defined as positive SARS-Cov-2 test (serology), plus fever (using self-reported questionnaire), or at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure (using self-reported questionnaire)	During the 6 months study period
Primary	Demonstrate cumulative incidence of hospitalization for COVID-19 among Health care workers:	Cumulative incidence of hospitalization for COVID-19	During the 6 months study period
Primary	Demonstrate the Incidence of specific Antibodies against SARS-CoV-2 at 3 and 6 months in health care workers	Incidence of specific Antibodies (IgG and IgM) against SARS-CoV-2 will be measured at 3 and 6 months	During the 6 months study period
Primary	Hospitalization of severe disease COVID-19	Number of participants who needed hospitalization	During the 6 months study period
Primary	Oxygen supplementation in severe disease COVID-19	Number of participants who Need for oxygen supplementation (nasal cannulas, masks, high flow oxygen) in hospitalized patients	During the 6 months study period
Primary	Need for intubation or non-invasive ventilation for the patient.	Number of participants who Need for intubation or non-invasive ventilation in hospitalized patients	During the 6 months study period
Primary	Critical care admission with SARS-CoV2	Number of participants in Critical care admission with SARS-CoV2 in hospitalized patients	During the 6 months study period
Primary	Mortality associated to progressive pulmonary disease	Mortality associated to progressive pulmonary disease in hospitalized patients	During the 6 months study period
Secondary	Evaluate the safety of the vaccine by measuring the incidence rates of local and systemic adverse effects that occur after one month its application.		1 month after vaccine/placebo application
Secondary	Calculate the incidence of COVID-19 complications		During the 6 months study period
Secondary	Determine the mean days of hospitalization and days in intensive care unit by COIVD-19		During the 6 months study period
Secondary	Calculate the cost associated with in-hospital medical care		During the 6 months study period
Secondary	Determine the scores of the Clinical Prediction Rules associated with mortality using Sequential Organ Failure Assessment (SOFA score) at the patient's hospital admission:	SOFA score: PaO2/FIO2 (mm Hg), SaO2/FIO2, Platelets (×10³/µL), Bilirubin (mg/dL), Hypotension, Glasgow Coma Score and Creatinine (mg/dL) or urine output (mL/d).	During the 6 months study period
Secondary	Determine the scores of the Clinical Prediction Rules associated with mortality using Acute Physiology and Chronic Health disease Classification System (APACHE) at the patient's hospital admission:	APACHE: History of severe organ failure or immunocompromise Heart Failure Class IV, cirrhosis, chronic lung disease, or dialysis-dependent, Age, Temperature (C°), Mean arterial pressure (mmHg), pH, Sodium (mEq/L), Potassium (mEq/L), Creatinine (mg/dL), Hematocrit (%), WBC (x 109/L)	During the 6 months study period
Secondary	Evaluate and determine the alteration profile in laboratory studies at the patient's hospital admission	CPR, ESR, Ferritin, D-dimer, LDH,Troponins, Procalcitonin, Interleukin-6, Hemoglobin, Hematocrit, Erythrocytes, Leukocytes, MCV, HCM, MCHC, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, Glucose, Urea, Creatinine, BUN, Sodium, Potassium, Chlorine, Calcium, Serum albumin, Direct bilirubin, Indirect bilirubin, Alkaline phosphatase, AST, ALT, bleeding time, Prothrombin Time, Activated partial thromboplastin time, Arterial / Venous Blood Gasometry, pH, pCO2, HCO3, pO2, SaO2%, Lactate.	During the 6 months study period
Secondary	Registration of chronic medications		During the 6 months study period
Secondary	Need for vasopressors		During the 6 months study period

External Links

•   Related Info
•   Related Info
•   Related Info
•   Related Info